Abstract

AbstractWith the massive influx of data from “omics” methods combined with sophisticated informatics platforms, personalized medicine, defined as the tailoring of medical decision‐making and/or treatments to an individual patient, has led to the promise of better and more efficient patient care. As a concept, personalized medicine could fundamentally alter how clinicians think about the diagnosis and treatment of disease. The introduction of a precision medicine tool has benefits for multiple stakeholders; patients benefit by having improved outcomes, physicians can make confident decisions in managing their patients, and the healthcare system saves significant dollars through the reduction of wasted spend. This paradigm has been particularly true in oncology where biomarker‐driven treatment paradigms have become increasingly common. In this review, personalized medicine and biomarkers in the field of dermatology are reviewed. Specifically, three disease states are discussed including psoriasis, atopic dermatitis, and melanoma. For each disease state, biomarkers and personalized medicine tests are reviewed focusing on diagnosis and treatment for these conditions. The ethics, implementation, advantages, and disadvantages are discussed for the adaptation of personalized medicine in clinical dermatology. The advent of personalized medicine in dermatology could lead to a paradigm shift in how patients are treated, with the resulting improved clinical outcomes leading to concomitant reductions in wasted healthcare expenditures.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.